市場調查報告書
商品編碼
1008134

橋本氏甲狀腺炎的診斷和治療的全球市場(2020年∼2026年)

Hashimoto's Thyroiditis Diagnosis and Treatment Market 2020-2026

出版日期: | 出版商: Orion Market Research Pvt Ltd | 英文 | 商品交期: 2-3個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

在預測期內,全球橋本甲狀腺炎市場將以相當大的年複合成長率成長。橋本氏甲狀腺炎是一種免疫系統攻擊甲狀腺並逐漸導致甲狀腺功能亢進的病症。

越來越多的自身免疫性甲狀腺疾病和碘缺乏導致了橋本甲狀腺炎治療需求的成長。此外,還有各種與甲狀腺疾病相關的國家健康計劃,提高了人們對此類疾病的認識,進一步推動了橋本甲狀腺炎市場的成長。

然而,對於橋本甲狀腺炎的藥物治療,食品和藥物管理有嚴格的規定,這對市場構成了障礙。儘管如此,橋本氏病的進一步研發和治療的成本效益將成為採用橋本氏甲狀腺炎治療的巨大機會。

本報告提供橋本氏甲狀腺炎的世界市場調查,市場概要,市場成長要素及阻礙因素分析,市場機會,各診斷、治療、通路、地區的市場規模的變化與預測,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 報告概要

第2章 市場概要與洞察

  • 調查範圍
  • 分析師的洞察和目前市場趨勢

第3章 競爭情形

  • 有競爭力的儀表板
  • 重要的策略分析
  • 主要企業分析
    • AbbVie Inc.
    • Pfizer Inc.
    • Merck KGaA
    • IBSAInstitutBiochimique SA

第4章 市場決策要素

  • 動機
  • 阻礙因素
  • 市場機會

第5章 市場細分化

  • 各診斷
    • 甲狀腺刺激素檢驗
    • 甲狀腺素試驗
    • 抗甲狀腺抗體檢驗
  • 各治療
    • 左旋甲狀腺素
    • 三碘甲腺原氨酸
    • 乾燥甲狀腺萃取物
    • 其他(三碘甲狀腺胺酸,丙硫氧嘧啶)
  • 各銷售管道
    • 醫院藥局
    • 零售藥局

第6章 地區分析

  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 英國
    • 德國
    • 義大利
    • 西班牙
    • 法國
    • 其他歐洲
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 其他地區

第7章 企業簡介

  • AcellaPharmaceuticals, LLC
  • Allergan plc
  • Bio-Rad Laboratories, Inc.
  • General Electric Co.
  • Intas Pharmaceuticals Ltd.
  • Jerome Stevens Pharmaceuticals, Inc.
  • Lannett Company, Inc.
  • Lupin Ltd.
  • Mylan NV
  • Novartis AG
  • RLC Labs
  • Taj Pharmaceuticals Ltd.
目錄
Product Code: OMR2023427

Global Hashimoto's Thyroiditis Diagnosis and Treatment Market Size, Share & Trends Analysis Report by Diagnosis (Thyroid-Stimulating Hormone Test, Thyroxine Test, Antithyroid Antibody Test), By Treatment (Levothyroxine, Triiodothyronine, Desiccated Thyroid Extract and other), Distribution Channel (Hospital Pharmacies, and Retail Pharmacies) Forecast Period 2021-2027

Global Hashimoto's thyroiditis market is anticipated to grow at a considerable CAGR during the forecast period. Hashimoto's thyroiditis is a condition in which the immune system attacks the thyroid and gradually leads to hyperthyroidism. Production of immune cells and autoantibodies by the body's immune system are characteristics of Hashimoto's thyroiditis, which can damage thyroid cells and compromise their ability to make thyroid hormones. There are various treatment methods for such diseases by using replacement agents such as levothyroxine, triiodothyronine, or desiccated thyroid extract. The increasing autoimmune thyroid diseases and deficiency of iodine are responsible for the growth in the demand for Hashimoto's Thyroiditis treatment. Furthermore, there are various national health programs related to thyroid disease that raise awareness regarding such diseases that further fuel the growth of Hashimoto's thyroiditis market.

However, there are stringent regulations of food and drug administration regarding medication of Hashimoto's Thyroiditis which acts as an obstacle for the market. Although, further research and development for Hashimoto's diseases and the cost-effectiveness of the treatment will turn out to be a huge opportunity for the adoption of Hashimoto's thyroiditis treatment.

Segmental Outlook

The global Hashimoto's thyroiditis market is segmented based on diagnosis, treatment, and distribution channels. In diagnosis, the market is segmented into Thyroid-stimulating hormone tests, thyroxine tests, antithyroid antibody tests. Moreover, based on treatment, the market is segmented into levothyroxine, triiodothyronine, desiccated thyroid extract, and others. By distribution channel, the treatment market is segmented into hospital pharmacies and retail pharmacies.

Source: OMR Global

Levothyroxine is a major treatment and is considered to dominate the market.

Levothyroxine is the first line of treatment for Hashimoto's thyroiditis and will be the dominating segment during the forecast period. Levothyroxine is a hormone medicine treatment for the underactive thyroid gland, the following medicine helps in replacing the missing thyroid hormone. The drug is available in the brand name such as Synthroid, Levoxyl, and Unithroid which are available as oral tablets, oral capsules, or injectable solutions. The medicine is a prescription drug and is used in form of combination therapy. Levothyroxine might be taken life-long while treating hypothyroidism unless the disease becomes transient.

Regional Outlooks

The global Hashimoto's thyroiditis market is further segmented based on geography into North America, Europe, Asia-Pacific, and the Rest of the World. North America is expected to have a significant market during the forecast period attributed to factors such as the large presence of healthcare facilities in the region, high awareness among the people about the diseases, strategic collaborations between the pharmaceutical companies and government organizations. As per ClinCalc LLC, Levothyroxine was the second most prescribed drug in the US in 2018, a rank higher than a year ago. Around 105 million prescriptions of Levothyroxine were registered in 2018 in the US. AbbVie Inc. is a major manufacturer of Levothyroxine as Synthroid. The company generated a revenue of $770-$780 million each year in the period 2018-2020 from the sale of Levothyroxine as Synthroid in the US.

Source: OMR Global

Asia-Pacific will have significant growth in the global Hashimoto's Thyroiditis Market

Asia Pacific is expected to register significant growth in Hashimoto's Thyroiditis market. The growth is attributed to rising healthcare infrastructure in emerging economies including China, India, and ASEAN countries, along with that rising insurance payer, development, and expansion of public and private healthcare sectors. Further one of the major reasons for the growth of the market in this region is huge investment is done by global companies in local companies of the region due to the presence of raw materials and labor at cheaper cost. The availability of generics in the region is also a major reason for the rise of the market.

Market Players Outlook

The key players of Hashimoto's thyroiditis market include AbbVie Inc., Pfizer Inc., Merck KGaA, IBSA Institut Biochimique SA, among others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers, and acquisitions, collaborations, and new product launches, to stay competitive in the market. For instance, in August 2020, Lannett Company, Inc., launched Cediprof, Inc.'s FDA-approved Levothyroxine Sodium Tablets USP, under the companies interim exclusive supply and distribution agreement in the US.

The Report Covers

Market value data analysis of 2020 and forecast to 2027.

Annualized market revenues ($ million) for each market segment.

Country-wise analysis of major geographical regions.

Key companies operating in the global Penicillin and Streptomycin

market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.

Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.

Analysis of market entry and market expansion strategies.

Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Competitive Dashboard
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AbbVie Inc.
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Pfizer Inc.
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Merck KGaA
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. IBSAInstitutBiochimique SA
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments

4. Market Determinants

  • 4.1. Motivators
  • 4.2. Restraints
  • 4.3. Opportunities

5. Market Segmentation

  • 5.1. Global Hashimoto's Thyroiditis Diagnosis and Treatment MarketbyDiagnosis
    • 5.1.1. Thyroid-Stimulating Hormone Test
    • 5.1.2. Thyroxine Test
    • 5.1.3. Antithyroid Antibody Test
  • 5.2. Global Hashimoto's Thyroiditis Diagnosis and Treatment Market by Treatment
    • 5.2.1. Levothyroxine
    • 5.2.2. Triiodothyronine
    • 5.2.3. Desiccated Thyroid Extract
    • 5.2.4. Other (Liothyronine, Propylthiouracil)
  • 5.3. Global Hashimoto's Thyroiditis Treatment Market byDistribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Retail Pharmacies

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. South Korea
    • 6.3.5. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. AcellaPharmaceuticals, LLC
  • 7.2. Allergan plc
  • 7.3. Bio-Rad Laboratories, Inc.
  • 7.4. General Electric Co.
  • 7.5. Intas Pharmaceuticals Ltd.
  • 7.6. Jerome Stevens Pharmaceuticals, Inc.
  • 7.7. Lannett Company, Inc.
  • 7.8. Lupin Ltd.
  • 7.9. Mylan NV
  • 7.10. Novartis AG
  • 7.11. RLC Labs
  • 7.12. Taj Pharmaceuticals Ltd.

LIST OF TABLES

  • 1. GLOBAL HASHIMOTO'S THYROIDITIS DIAGNOSIS AND TREATMENT MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 2. GLOBAL THYROID-STIMULATING HORMONE TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 3. GLOBAL THYROXINE TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 4. GLOBAL ANTITHYROID ANTIBODY TEST MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)

5. GLOBAL HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY TREATMENT,

  • 6. GLOBAL LEVOTHYROXINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 7. GLOBAL TRIIODOTHYRONINE MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 8. GLOBAL OTHER DRUG MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 9. GLOBAL HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 10. GLOBAL HOSPITAL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION, 2020-2027 ($ MILLION)
  • 11. GLOBAL RETAIL PHARMACIES MARKET RESEARCH AND ANALYSIS BY REGION 2020-2027 ($ MILLION)
  • 12. NORTH AMERICAN HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 13. NORTH AMERICAN HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 14. NORTH AMERICAN HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 15. NORTH AMERICAN HASHIMOTO'S THYROIDITIS TREATMENT MARKET RESEARCH AND ANALYSIS BYDISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 16. EUROPEAN HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 17. EUROPEAN HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 18. EUROPEAN HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 19. EUROPEAN HASHIMOTO'S THYROIDITIS TREATMENT MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 20. ASIA-PACIFIC HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2020-2027 ($ MILLION)
  • 21. ASIA-PACIFIC HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 22. ASIA-PACIFIC HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 23. ASIA-PACIFIC HASHIMOTO'S THYROIDITIS TREATMENT MARKET RESEARCH AND ANALYSIS BYDISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)
  • 24. REST OF THE WORLD HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY DIAGNOSIS, 2020-2027 ($ MILLION)
  • 25. REST OF THE WORLD HASHIMOTO'S TREATMENT THYROIDITIS MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2020-2027 ($ MILLION)
  • 26. REST OF THE WORLD HASHIMOTO'S THYROIDITIS MARKET RESEARCH AND ANALYSIS BY DISTRIBUTION CHANNEL, 2020-2027 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL HASHIMOTO'S THYROIDITIS MARKET SHARE BY DIAGNOSIS, 2020 VS 2027 (%)
  • 2. GLOBAL HASHIMOTO'S THYROIDITIS MARKET SHARE BY TREATMENT, 2020 VS 2027 (%)
  • 3. GLOBAL HASHIMOTO'S THYROIDITIS TREATMENT MARKET SHARE BYDISTRIBUTION CHANNEL, 2020 VS 2027 (%)
  • 4. GLOBAL HASHIMOTO'S THYROIDITIS MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 5. GLOBAL THYROID-STIMULATING HORMONE TEST MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 6. GLOBAL THYROXINE TEST MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 7. GLOBAL ANTITHYROID ANTIBODY TESTMARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 8. GLOBAL LEVOTHYROXINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 9. GLOBAL TRIIODOTHYRONINE MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 10. GLOBAL DESICCATED THYROID EXTRACT MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 11. GLOBAL HOSPITAL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 12. GLOBAL RETAIL PHARMACIES MARKET SHARE BY GEOGRAPHY, 2020 VS 2027 (%)
  • 13. US HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 14. CANADA HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 15. UK HASHIMOTO'S THYROIDITIS AND THYROXINE TESTMARKET SIZE, 2020-2027($ MILLION)
  • 16. FRANCE HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 17. GERMANY HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 18. ITALY HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 19. SPAIN HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 20. REST OF EUROPE HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 21. INDIA HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 22. CHINA HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 23. JAPAN HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 24. SOUTH KOREA HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 25. REST OF ASIA-PACIFIC HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)
  • 26. REST OF THE WORLD HASHIMOTO'S THYROIDITIS MARKET SIZE, 2020-2027($ MILLION)